Abiraterone
Formulations: - Oral > Solid: 250 mg; 500 mg Indications: - Malignant neoplasms of prostate Source: EML workbook import
Imported from EML workbook.
Formulations: - Oral > Solid: 250 mg; 500 mg Indications: - Malignant neoplasms of prostate Source: EML workbook import
Formulations: - Oral > Solid: 1 mg tablet Indications: - Other specified malignant neoplasms of breast - Malignant neoplasms of breast Source: EML workbook import
Formulations: - Oral > Solid: 50 mg Indications: - Malignant neoplasms of prostate Source: EML workbook import
Formulations: - Oral > Solid: 40 mg Indications: - Malignant neoplasms of prostate Source: EML workbook import
Indications: - Malignant neoplasms of prostate Source: EML workbook import
Indications: - Malignant neoplasms of breast - Malignant neoplasms of prostate Source: EML workbook import
Formulations: - Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe Indications: - Malignant neoplasms of breast - Malignant neoplasms of prostate Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate) Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection Indications: - Burkitt lymphoma including Burkitt leukaemia - Lymphoid leukaemia, not elsewhere classified Source: EML workbook import
Indications: - Malignant neoplasms of prostate Source: EML workbook import
Formulations: - Oral > Solid: 10 mg (as citrate); 20 mg (as citrate) Indications: - Other specified malignant neoplasms of breast - Malignant neoplasms of breast Source: EML workbook import
Indications: - Malignant neoplasms of breast - Malignant neoplasms of prostate Source: EML workbook import
Ready to amplify your rewards? Drop your email and we'll be in touch soon.